Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple sclerosis

Repurposing dopaminergic drugs for MS — the evidence mounts

A new study has shown that both in patients with multiple sclerosis (MS) and in healthy controls, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear cells. The finding adds to previous evidence for the potential benefit of dopaminergic drugs in MS.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: IFN-β could alleviate dysfunction of dopaminergic pathways in multiple sclerosis (MS).

References

  1. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B. & Hartung, H. P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2, 201–211 (2006).

    CAS  Article  Google Scholar 

  2. Tzartos, J. S. et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008).

    CAS  Article  Google Scholar 

  3. Melnikov, M., Belousova, O., Murugin, V., Pashenkov, M. & Boyko, A. The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J. Neuroimmunol. 292, 97–101 (2016).

    CAS  Article  Google Scholar 

  4. Cosentino, M. & Marino, F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J. Neuroimmune Pharmacol. 8, 163–179 (2013).

    Article  Google Scholar 

  5. Beaulieu, J.-M. & Gainetdinov, R. R. The physiology, signalling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182–217 (2011).

    CAS  Article  Google Scholar 

  6. Sarkar, C., Basu, B., Chakroborty, D., Dasgupta, P. S. & Basu, S. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24, 525–528 (2010).

    CAS  Article  Google Scholar 

  7. Levite, M. in Nerve-Driven Immunity — Neurotransmitters and Neuropeptides in the Immune System Ch. 1 (ed. Levite, M.) 1–45 (Springer-Verlag, Wien, 2012).

    Book  Google Scholar 

  8. Pacheco, R., Contreras, F. & Zouali, M. The dopaminergic system in autoimmune diseases. Front. Immunol. 5, 117 (2014).

    Article  Google Scholar 

  9. Cosentino, M. et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109, 632–642 (2007).

    CAS  Article  Google Scholar 

  10. Venken, K., Hellings, N., Liblau, R. & Stinissen, P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 16, 58–68 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marco Cosentino.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Marino, F., Cosentino, M. Repurposing dopaminergic drugs for MS — the evidence mounts. Nat Rev Neurol 12, 191–192 (2016). https://doi.org/10.1038/nrneurol.2016.33

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.33

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing